Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: survival + 156 + web  Related to the article below (Last Update: 8/4/2008)

Full Text
Science Magazine (subscription) - Jul 31, 2008
The reservoir had begun filling 3 years earlier and has risen from its original low water mark of 62 meters to the present 156 meters. ...
Global Heating: Why We Must Shift to Carbon-Free Fuel: The Doers ...
Huffington Post, NY - Jul 22, 2008
With billions of dollars in future sales and their very survival at stake, almost all the major ones believe hydrogen is the long-term key to reducing the ...
Source: Google News

… of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival … -
TR Pedersen, K Berg, TJ Cook, O Faergeman, T … - Archives of Internal Medicine, 1996 - Am Med Assoc
... this message because your Web browser does not support basic Web standards ... 156 No ...
with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. ...

Depressive affect and survival among gay and bisexual men infected with HIV -
TJ Mayne, E Vittinghoff, MA Chesney, DC Barrett, … - Archives of Internal Medicine, 1996 - Am Med Assoc
... your Web browser does not support basic Web standards ... J. Psychiatry 1999;156:101-
107 ... Depressed Mood and Survival in Seriously Ill Hospitalized Adults Roach et al ...

Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham … -
RJ Goldberg, M Larson, D Levy - Archives of Internal Medicine, 1996 - Am Med Assoc
... seeing this message because your Web browser does not support basic Web standards. ...
156 No ... Factors associated with survival to 75 years of age in middle-aged men ...

[BOOK] The Healing Web: Social Networks and Human Survival
M Pilisuk, SH Parks - 1986 - University Press of New England

Effect of comprehensive intervention program on survival of patients with human immunodeficiency … -
F Laraque, A Greene, JW Triano-Davis, R Altman, A … - Archives of Internal Medicine, 1996 - Am Med Assoc
... this message because your Web browser does not support basic Web standards ... 156 No ...
Effect of comprehensive intervention program on survival of patients with human ...

Duration of the survival benefit of zidovudine therapy in HIV infection -
RD Moore, JC Keruly, RE Chaisson - Archives of Internal Medicine, 1996 - Am Med Assoc
... seeing this message because your Web browser does not support basic Web standards ...
156 No ... Duration of the survival benefit of zidovudine therapy in HIV infection. ...

Pneumonia in a long-term care facility. A prospective study of outcome -
RR Muder, C Brennen, DL Swenson, M Wagener - Archives of Internal Medicine, 1996 - Am Med Assoc
... seeing this message because your Web browser does not support basic Web standards. ...
156 No ... Index of Charlson et al, were recorded End points were survival at 14 ...

Adverse 5-year outcome after coronary artery bypass surgery in blacks -
RJ Gray, S Nessim, SS Khan, T Denton, JM Matloff - Archives of Internal Medicine, 1996 - Am Med Assoc
... seeing this message because your Web browser does not support basic Web standards ...
156 No ... We studied the effects of medical risk factors on survival outcome after ...

Feeding rate may affect dispersal in the orb-web spider Nephila clavata -
T Miyashita - Oecologia, 1992 - Springer
... The orb-web spider Nephila clavata is a large species, common in ... spiders was the
same at the two sites (156 m 2) so that comparison of survival rate between ...

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and … -
NK Ibrahim, DK Frye, AU Buzdar, RS Walters, GN … - Archives of Internal Medicine, 1996 - Am Med Assoc
... this message because your Web browser does not support basic Web standards. ... 156 No. ...
The Kaplan-Meier survival curves were plotted and tested by the generalized ...

Source: Google Scholar
 
 

Five-year Study By OHSU Cancer Institute Shows Gleevec's Excellent Survival Rate

Article Date: 14 Dec 2006 - 9:00 PST
In five years Gleevec, the little yellow pill, has proved itself to be a miracle drug for most patients who take it.

When the drug first was developed by Brian J. Druker, M.D., the leukemia program leader of the Oregon Health & Science University Cancer Institute, the overall survival rate for patients with chronic myelogenous leukemia (CML) taking this new experimental drug was unknown.

"We've completely changed the outlook for patients with this disease. Before Gleevec, patients were fortunate if they lived five years. Now, we've given patients a hopeful future," said Druker, the principal investigator for the study.

Today, after five years, the overall survival of 553 subjects randomized to receive Gleevec as their initial therapy is nearly 90 percent, 95 percent if only deaths related to CML are considered. Just 5 percent of subjects discontinued Gleevec because of side effects. The results are published in the New England Journal of Medicine.

This study also shows that the risk of relapse has trended downward during the past three years. In the study's fifth year, less than 1 percent of patients progressed from the chronic phase to more advanced phases of the disease.

"This trend, coupled with the low risk of relapse, means that the possibility of long-term survival with CML is increasingly likely," Druker said.

The five-year study was conducted at 117 centers in 16 countries.

Article continues below and (thank you)
 
Gleevec also has a larger story to tell. Its targeted therapy approach broke new ground in how to treat cancer. By specifically targeting the cancerous cells, the healthy cells are left unharmed. Gleevec is changing cancer research and the drug is a harbinger of new agents for curing or controlling all cancers. "We are at an important juncture," Druker said, "not unlike the early 1900s where scientists turned infectious diseases from routinely fatal into manageable, curable or preventable diseases. We are on the cusp of turning cancer into a manageable disease."

Gleevec is a signal transduction inhibitor that interferes with the enzymes that trigger the growth of cancerous cells. Gleevec acts on CML cells by inhibiting the disease-causing enzyme BCR-ABL that tells cells to grow and divide.

Gleevec has also been approved for people with advanced gastrointestinal stromal tumors, dermatofibrosarcoma protuberans, Philadelphia chromosome-positive acute lymphoblastic leukemia, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and aggressive systemic mastocytosis.

Gleevec was co-developed and marketed by the pharmaceutical company Novartis.

Brian Druker, M.D., is the JELD-WEN Chair of Leukemia Research at the Oregon Health & Science University Cancer Institute and an Investigator of the Howard Hughes Medical Institute.

###

The OHSU Cancer Institute is the only cancer center designated by the National Cancer Institute between Sacramento and Seattle. It comprises some 120 clinical researchers, basic scientists and population scientists who work together to translate scientific discoveries into longer and better lives for Oregon's cancer patients. In the lab, basic scientists examine cancer cells and normal cells to uncover molecular abnormalities that cause the disease. This basic science informs more than 200 clinical trials conducted at the OHSU Cancer Institute.

Contact: Christine Decker
Oregon Health & Science University

 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News9A ;